Not Yet RecruitingNot Applicable

Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR

China36 participantsStarted 2026-04-11

Plain-language summary

This study aims to evaluate the effects of conservative management versus surgical intervention (adenoidectomy alone or adenotonsillectomy) on symptoms and local IgE levels in children with allergic rhinitis (AR) accompanied with adenotonsillar hypertrophy. The primary objectives include the impact of conservative management and surgical interventions on AR symptoms and local IgE levels. The second outcomes include serum IgE levels, inflammatory cell profiles within the nasal mucosa, and postoperative complications.

Who can participate

Age range3 Years – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Children with physician-diagnosed allergic rhinitis and typical symptoms (nasal obstruction, watery rhinorrhea, paroxysmal sneezing);
✓. Co-existing adenoidal and tonsillar hypertrophy meeting surgical indications;
✓. No systemic or topical corticosteroids, leukotriene antagonists, or antihistamines within the past 3 months.

Exclusion criteria

✕. Prior adenoidectomy, tonsillectomy, or radio-frequency ablation;
✕. Nasal polyps, cystic fibrosis, primary ciliary dyskinesia, fungal rhinosinusitis, systemic vasculitis/granulomatosis, tumor, or immunodeficiency;
✕. Endoscopic nasal surgery within 6 months or severe asthma precluding surgery;
✕. Upper respiratory infection within 4 weeks;
✕. Serious metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease, or any condition judged by the investigator to interfere with outcome assessment or participant safety;
✕. Currently enrolled or within 30 days of participation in another clinical trial.

What they're measuring

Symptom scores

Timeframe: Surgery Group: at baseline (Pre-surgery) and at 1, 3, and 6 months post-surgery; Medication Group: at baseline (Pre-treatment ) and at 1, 3, and 6 months post-treatment initiation.

Allergen-Specific IgE Levels in Nasal Cavity

Timeframe: Surgery Group: at baseline (Pre-surgery) and at 1, 3, and 6 months post-surgery; Medication Group: at baseline (Pre-treatment ) and at 1, 3, and 6 months post-treatment initiation.

Trial details

NCT IDNCT07527260

SponsorTongji Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-04-01

Contact for this trial

Yin Yao

+8615071077020 Dr.yaoyin@hotmail.com

View on ClinicalTrials.gov More Adenoidectomy trials

Plain-language summary

Who can participate

Age range3 Years – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Children with physician-diagnosed allergic rhinitis and typical symptoms (nasal obstruction, watery rhinorrhea, paroxysmal sneezing);
✓. Co-existing adenoidal and tonsillar hypertrophy meeting surgical indications;
✓. No systemic or topical corticosteroids, leukotriene antagonists, or antihistamines within the past 3 months.

Exclusion criteria

✕. Prior adenoidectomy, tonsillectomy, or radio-frequency ablation;
✕. Nasal polyps, cystic fibrosis, primary ciliary dyskinesia, fungal rhinosinusitis, systemic vasculitis/granulomatosis, tumor, or immunodeficiency;
✕. Endoscopic nasal surgery within 6 months or severe asthma precluding surgery;
✕. Upper respiratory infection within 4 weeks;
✕. Serious metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease, or any condition judged by the investigator to interfere with outcome assessment or participant safety;
✕. Currently enrolled or within 30 days of participation in another clinical trial.

What they're measuring

Symptom scores

Timeframe: Surgery Group: at baseline (Pre-surgery) and at 1, 3, and 6 months post-surgery; Medication Group: at baseline (Pre-treatment ) and at 1, 3, and 6 months post-treatment initiation.

Allergen-Specific IgE Levels in Nasal Cavity

Timeframe: Surgery Group: at baseline (Pre-surgery) and at 1, 3, and 6 months post-surgery; Medication Group: at baseline (Pre-treatment ) and at 1, 3, and 6 months post-treatment initiation.